

# The Right Therapy, for the Right Patients, at the Right Time.

<b>NSCLC</b> 	<p><b>ALK (D5F3) Rabbit Monoclonal Primary Antibody</b> Aid in identifying patients eligible for treatment with XALKORI® (crizotinib), ZYKADIA® (ceritinib), ALECENSA® (alectinib), or lorlatinib. <i>Ordering Number: 06679072001 – 50 tests</i></p>	<p><b>ROS1 (SP384) Rabbit Monoclonal Primary Antibody</b> May be used to aid in the identification of non-small cell lung cancer (NSCLC) with ROS1 expression for further characterization by a molecular and/or cytogenetic method. <i>Ordering Number: 09365575001 – 50 tests</i></p>
	<p><b>PD-L1 (SP142) Assay</b> Aid for identifying patients for treatment with TECENTRIQ® (atezolizumab). <i>Ordering Number: 08008540001 – 50 tests</i></p>	<p><b>PD-L1 (SP263) Assay</b> Aid in identifying patients for treatment with IMFINZI™ (durvalumab), KEYTRUDA® (pembrolizumab), LIBTAYO® (cemiplimab), TECENTRIQ® (atezolizumab) and in non-squamous NSCLC may be associated with enhanced survival from OPDIVO® (nivolumab). <i>Ordering Number: 07419821001 – 50 tests</i></p>
<b>BREAST</b> 	<p><b>Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody</b> ER (SP1) is a powerful predictor of response to hormone therapy and clinical outcome of breast cancer patients.<sup>1,2</sup> <i>Ordering Number: 05278406001 – 50 tests, 05278414001 – 250 tests</i></p>	<p><b>HER2 Dual ISH DNA Probe Cocktail</b> Aid in the assessment of patients for whom Herceptin (trastuzumab) is being considered. <i>Ordering Number: 08314373001 – 30 tests</i></p>
	<p><b>HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx</b> For treatment with trastuzumab (IHC 3+ or IHC 2+/ISH amplified), pertuzumab (IHC 3+ or IHC 2+/ISH amplified), trastuzumab emtansine (IHC 3+ or IHC 2+/ISH amplified), or trastuzumab deruxtecan (IHC 0 with membrane staining, IHC 1+ or IHC 2+/ISH non-amplified). <i>Ordering Number: 09670564001 – 50 tests</i></p>	<p><b>PD-L1 (SP142) Assay</b> First test to identify patients eligible for immunotherapy in triple-negative breast cancer (TNBC). <i>Ordering Number: 08008540001 – 50 tests</i></p>
	<p><b>HER2/neu (4B5) Rabbit Monoclonal Primary Antibody</b> Aid in the assessment of breast and gastric cancer patients for whom Herceptin treatment is considered. <i>Ordering Number: 05999570001 – 50 tests</i></p>	<p><b>Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody</b> PR (1E2) status provides an independent and significant tool for predicting hormone therapy response and clinical outcome.<sup>1,2</sup> <i>Ordering Number: 05277990001 – 50 tests, 05278392001 – 250 tests</i></p>
<b>GASTRIC</b> 	<p><b>HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx</b> The IHC device is indicated as a companion diagnostic for identifying patients who are eligible for treatment with the following therapies in accordance with the approved therapeutic labeling: Gastric carcinoma patients for treatment with trastuzumab (IHC 3+ or IHC 2+/ISH amplified), BTC patients for treatment with zanidatamab (IHC 3+). <i>Ordering Number: 09670564001 – 50 tests</i></p>	<p><b>HER2 Dual ISH DNA Probe Cocktail</b> Aid in the assessment of breast and gastric cancer patients for whom Herceptin treatment is considered. <i>Ordering Number: 08314373001 – 30 tests</i></p>
	<p><b>HER2/neu (4B5) Rabbit Monoclonal Primary Antibody</b> Aid in the assessment of breast and gastric cancer patients for whom Herceptin treatment is considered. <i>Ordering Number: 05999570001 – 50 tests</i></p>	<p><b>CLDN18 (43-14A) RxDx Assay</b> Helps identify patients with gastric or GEJ adenocarcinoma eligible for VYLOY™ (zolbetuximab) treatment. <i>Ordering Number: 08285918001 – 50 tests</i></p>
<b>GYNECOLOGIC</b> 	<p><b>CINtec® p16 Histology</b> Validated p16 IHC diagnostic test for evaluation of cervical biopsies. <i>Ordering Number: 06695248001 – 50 tests, 06695256001 – 250 tests</i></p>	<p><b>CINtec® PLUS Cytology</b> Dual-stain triage test for patients with a positive high-risk HPV (hrHPV) result. Uses dual-biomarker technology to simultaneously detect p16 and Ki-67 within a cell. <i>Ordering Number: 06889565001 – 100 tests</i></p>
	<p><b>FOLR1 (FOLR1-2.1) RxDx Assay</b> Helps identify patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer eligible for ELAHERE (mirvetuximab soravtansine) treatment. <i>Ordering Number: 07763620001 – 50 tests</i></p>	<p><b>MMR RxDx Panel</b> Indicated to identify patients eligible for therapy based on MMR status. <b>MMR RxDx Panel, VENTANA includes:</b> anti-MLH1 (M1), Mouse Monoclonal Primary Antibody (08033668001) anti-PMS2 (A16-4), Mouse Monoclonal Primary Antibody (08033692001) anti-MSH2 (G219-1129), Mouse Monoclonal Primary Antibody (08033684001) anti-MSH6 (SP93), Mouse Monoclonal Primary Antibody (08033676001) anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody (08033676001)</p>
<b>BLADDER</b> 	<p><b>PD-L1 (SP142) assay</b> Aid to identify UC patients who are most likely to benefit from TECENTRIQ®. <i>Ordering Number: 08008540001 – 50 tests</i></p>	<p><b>Visit us today and explore our portfolio:</b></p>
<b>SOLID TUMOURS</b> 	<p><b>pan-TRK (EPR17341) Assay</b> Used to identify the C-terminal region of TRK A, B and C. <i>Ordering Number: 08494665001 – 50 tests</i></p>	
<b>COLORECTAL</b> 	<p><b>MMR IHC Panel</b> Aid to differentiate between sporadic colorectal cancer + probable Lynch syndrome. <b>MMR IHC Panel, VENTANA includes:</b> anti-MLH1 (M1), Mouse Monoclonal Primary Antibody (08033668001) anti-PMS2 (A16-4), Mouse Monoclonal Primary Antibody (08033692001) anti-MSH2 (G219-1129), Mouse Monoclonal Primary Antibody (08033684001) anti-MSH6 (SP93), Mouse Monoclonal Primary Antibody (08033676001) anti-BRAF V600E (VE1), Mouse Monoclonal Primary Antibody (08033706001)</p>	
<b>DERMATOLOGY</b> 	<p><b>PRAME (EPR20330) Rabbit Monoclonal Primary Antibody</b> Assists with accurate diagnosis of melanoma or nevus by highlighting melanoma cells.* <i>Ordering Number: 09592237001 – 50 tests, 09592245001 – 250 tests</i></p>	

\*In conjunction with morphologic evaluation on H&E and correlation with clinical findings and/or additional ancillary tests when applicable. 1) Allison, K et al. Estrogen and Progesterone Receptor Testing in Breast Cancer. Arch Pathol Lab Med. 2019. 2) Fitzgibbons, P. et al. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast. College of American Pathologists. 2020